Patents Assigned to ALZINOVA AB
  • Stable amyloid beta monomers and oligomers
    Patent number: 10138281
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: November 27, 2018
    Assignee: ALZINOVA AB
    Inventors: Torleif Härd, Anders Sandberg
  • Method of immunization for reducing toxic damaged caused by oligomeric form of the amyloid-beta protein with stable amyloid beta monomers and oligomers
    Patent number: 10023622
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 17, 2018
    Assignee: ALZINOVA AB
    Inventors: Torleif Härd, Anders Sandberg
  • STABLE AMYLOID BETA MONOMERS AND OLIGOMERS
    Publication number: 20180030103
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Application
    Filed: May 19, 2017
    Publication date: February 1, 2018
    Applicant: ALZINOVA AB
    Inventors: Torleif HÄRD, Anders SANDBERG
  • Stable amyloid beta monomers and oligomers
    Patent number: 9688734
    Abstract: The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: June 27, 2017
    Assignee: ALZINOVA AB
    Inventors: Torleif Härd, Anders Sandberg
  • ANTI OLIGOMER ANTIBODIES AND USES THEREOF
    Publication number: 20130344089
    Abstract: The present invention relates to antibodies and antibody fragments specific for the toxic prefibrillar aggregates of amyloid-beta peptides, and uses thereof, for example in the diagnosis and treatment of amyloid diseases such as Alzheimer's disease and related disorders. The invention further provides methods for the identification of compounds potentially useful for the treatment of an amyloid disease, such as Alzheimer's disease.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: ALZINOVA AB
    Inventors: Anna Sjoblom-Hallen, Anders Sandberg